Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:272:267-285.
doi: 10.1007/164_2021_569.

Novel Immunosuppression in Solid Organ Transplantation

Prasad Konda  1 , Reshma Golamari  2 , Howard J Eisen  3
Affiliations

Novel Immunosuppression in Solid Organ Transplantation

Prasad Konda et al. Handb Exp Pharmacol. 2022.

Abstract

Solid organ transplantation and survival has improved tremendously in the last few decades, much of the success has been attributed to the advancements in immunosuppression. While steroids are being replaced and much of the immunosuppressive strategies focus on steroid free regimens, novel agents have introduced in the induction, maintenance, and treatment of acute rejection phase. MTOR inhibitors have helped with the renal sparing side effect from the calcineurin inhibitors, newer agents such as rituximab have decreased the incidence of donor-specific antibodies which led to decreased incidence of acute rejection reactions. In this chapter we discuss the newer therapies directed specifically for solid organ transplantation.

Keywords: Heart transplantation; Immunosuppression.

PubMed Disclaimer

References

    1. Aguero J, Almenar L, Martínez-Dolz L, Moro JA, Rueda J, Raso R et al (2008) Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clin Transpl 22(1):98–106. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-0012.2007.00751.x
    1. Alishetti S, Farr M, Jennings D, Serban G, Uriel N, Sayer G et al (2020) Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant 20(12):3620–3630 - PubMed - PMC - DOI
    1. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E et al (2014) Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 14(8):1828–1838 - PubMed - DOI
    1. Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D et al (2019) Blood pressure in de novo heart transplant recipients treated with everolimus compared with a cyclosporine-based regimen: results from the randomized SCHEDULE trial. Transplantation 103(4):781–788 - PubMed - DOI
    1. Anne K, Meroula R, Peter R, Phillip S, Andrew G, Gerry O’D et al (2004) Sirolimus in De Novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 110(17):2694–2700. https://www.ahajournals.org/doi/10.1161/01.CIR.0000136812.90177.94 - DOI

MeSH terms